Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

Alexander Shulgin, ‘Godfather’ of Psychedelic Drugs, Dies at 88

(Reuters) — Alexander Shulgin, who over the course of 40 years of scientific research created some 200 psychedelic compounds, earning the nickname “Godfather of ecstasy” for his pioneering work with the drug, has died at the age of 88.

Shulgin died on Monday at his home in Northern California, “surrounded by family and caretakers and Buddhist meditation music,” according to a Facebook post by his wife and research partner, Ann.

Though he is best known for popularizing the once-obscure drug now known to the world as MDMA, or ecstasy, some 60 years after it was first patented, Shulgin is credited with creating some 200 other psychoactive compounds.

“I’ve always been interested in the machinery of the mental process,” he told the New York Times in a 2005 interview at his home laboratory.

A native of Berkeley, California, Shulgin studied organic chemistry at Harvard before dropping out to join the U.S. Navy during World War Two, according to a biography on his official website.

Following his service, he earned his PhD in biochemistry from the University of California at Berkeley and went to work as a chemist for the Dow Chemical Company, where he took a strong interest in psychopharmacology after taking mescaline and having what he called a profound experience.

Shulgin, who left Dow in 1965, famously first tested many of his drugs on himself, his wife and his friends.

He first began studying MDMA in 1976 after a graduate student brought the drug to his attention, and he became first to document its effect on humans, long before it became popular in nightclubs.

In 1992 Shulgin and his wife published PiHKAL (Phenethylamines I Have Known and Loved): A Chemical Love Story, a book described by the Times as a “thinly fictionalized” account of his and Ann’s lives combined with descriptions of 179 drugs and their synthesis.

The paper said that book made Shulgin both an underground celebrity and a target for the U.S. Drug Enforcement Administration, which raided his home and lab in 1993.

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning journalism this Passover.

In this age of misinformation, our work is needed like never before. We report on the news that matters most to American Jews, driven by truth, not ideology.

At a time when newsrooms are closing or cutting back, the Forward has removed its paywall. That means for the first time in our 126-year history, Forward journalism is free to everyone, everywhere. With an ongoing war, rising antisemitism, and a flood of disinformation that may affect the upcoming election, we believe that free and open access to Jewish journalism is imperative.

Readers like you make it all possible. Right now, we’re in the middle of our Passover Pledge Drive and we need 500 people to step up and make a gift to sustain our trustworthy, independent journalism.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Our Goal: 500 gifts during our Passover Pledge Drive!

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.